Case Study

Phase 1 Dose Escalation Study With A Bispecific Antibody In Relapse Refractory Multiple Myeloma (RRMM)

Cerba Research Performing 220+ Routine & Specialty Tests

Scope

Patients Screened: 248

Patients Enrolled: 183

Sites: 11

Countries: 2

Regions: US, EU

Study duration: 43 months

Cerba Research involved in 220+routine & specialty tests such as FCM, FISH, CD138+ cell isolation & count

Timeline

May '19	Nov '22	Dec '22	
•	•	•	
FPFV	LPLV	DBL	
Challenges		Solutions	

Cerba Research involved in 220+ tests

Such as CD138+ cell isolation & count, BCMA, TBNK lymphocyte FCM, T-cell subsets FCM and more

- ↑ Flexibility in working with referral labs & subcontractor labs
- ↑ FCM in-house design & validation

Cerba Research Data In-house (MSN F55); RRMM=Relapsed or Refractory Multiple Myeloma; FCM=Flow CytoMetry; FISH=Fluorescence In-Situ Hybridization; FPFV=First-Patient First-Visit; LPLV=Last-Patient Last-Visit; DBL=DataBase Lock



CERBA RESEARCH HO Industriepark Zwijnaarde 3 info@cerbaresearch.com 9052 Gent, Belgium

Tel: +32 9 329 23 29 www.cerbaresearch.com

- ↑ +25,000 samples managed to date
- ↑ Strong FCM expertise

Key Achievments

↑ Continued partnership with the large CRO & Sponsor on liquid tumor trials